CR20230130A - Proceso e intermedios para preparar un inhibidor de jak1 - Google Patents
Proceso e intermedios para preparar un inhibidor de jak1Info
- Publication number
- CR20230130A CR20230130A CR20230130A CR20230130A CR20230130A CR 20230130 A CR20230130 A CR 20230130A CR 20230130 A CR20230130 A CR 20230130A CR 20230130 A CR20230130 A CR 20230130A CR 20230130 A CR20230130 A CR 20230130A
- Authority
- CR
- Costa Rica
- Prior art keywords
- preparing
- intermediates
- jak1 inhibitor
- jak1
- inhibitor
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 2
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 title 1
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 abstract 1
- 229950001890 itacitinib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Health & Medical Sciences (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Chemistry (AREA)
Abstract
La presente invención se refiere a procesos para preparar itacitinib, o una sal de este, e intermedios sintéticos relacionados que se relacionan con estos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063067062P | 2020-08-18 | 2020-08-18 | |
PCT/US2021/046286 WO2022040172A1 (en) | 2020-08-18 | 2021-08-17 | Process and intermediates for preparing a jak1 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230130A true CR20230130A (es) | 2023-07-13 |
Family
ID=77693614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230130A CR20230130A (es) | 2020-08-18 | 2021-08-17 | Proceso e intermedios para preparar un inhibidor de jak1 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11897889B2 (es) |
EP (1) | EP4200278A1 (es) |
JP (1) | JP2023538614A (es) |
KR (1) | KR20230095923A (es) |
CN (1) | CN117043152A (es) |
AR (1) | AR123268A1 (es) |
AU (1) | AU2021329301A1 (es) |
BR (1) | BR112023002939A2 (es) |
CA (1) | CA3192055A1 (es) |
CL (1) | CL2023000482A1 (es) |
CO (1) | CO2023003286A2 (es) |
CR (1) | CR20230130A (es) |
EC (1) | ECSP23019419A (es) |
IL (1) | IL300557A (es) |
MX (1) | MX2023002035A (es) |
PE (1) | PE20231308A1 (es) |
TW (1) | TW202212341A (es) |
WO (1) | WO2022040172A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11905292B2 (en) | 2020-08-18 | 2024-02-20 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
CA3226714A1 (en) * | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB812366A (en) | 1955-08-18 | 1959-04-22 | Wellcome Found | Improvements in and relating to derivatives of pyrimidine and the preparation thereof |
US5102904A (en) | 1989-12-08 | 1992-04-07 | American Cyanamid Company | N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas |
WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
WO2005116035A1 (en) | 2004-05-27 | 2005-12-08 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
EP1913000B1 (en) | 2005-07-29 | 2012-01-11 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
CN2928286Y (zh) | 2006-01-06 | 2007-08-01 | 水城钢铁(集团)有限责任公司 | 预入口导卫装置 |
CN101379061B (zh) | 2006-02-02 | 2016-06-15 | 千禧药品公司 | E1活化酶抑制剂 |
EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
KR20100038119A (ko) | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 raf 억제제로서 이의 용도 |
BRPI0820544A2 (pt) | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
KR20120108042A (ko) | 2008-03-11 | 2012-10-04 | 인사이트 코포레이션 | Jak 억제제로서의 아제티딘 및 시클로부탄 유도체 |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
US20120022058A1 (en) | 2009-04-10 | 2012-01-26 | Pfizer Inc. | 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
TWI484962B (zh) | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為jak抑制劑之3-〔4-(7h-吡咯并〔2,3-d〕嘧啶-4-基)-1h-吡唑-1-基〕辛烷或庚腈 |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
EP2486041B1 (en) | 2009-10-09 | 2013-08-14 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
WO2011063159A1 (en) | 2009-11-18 | 2011-05-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20110207754A1 (en) | 2010-02-18 | 2011-08-25 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
KR102354472B1 (ko) | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
JP5876146B2 (ja) | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体 |
CN103732597B (zh) * | 2011-08-12 | 2016-08-17 | 日产化学工业株式会社 | 三环杂环化合物和jak抑制剂 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
HUE055894T2 (hu) | 2012-11-15 | 2021-12-28 | Incyte Holdings Corp | A ruxolitinib nyújtott felszabadulású dózisformái |
PE20151902A1 (es) | 2013-03-06 | 2015-12-26 | Incyte Corp | Proceso e intermedios para hacer un inhibidor de jak |
SI3527263T1 (sl) | 2013-05-17 | 2021-05-31 | Incyte Corporation | Derivati bipirazola kot zaviralci JAK |
EP3721873A1 (en) | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
TW201625643A (zh) | 2014-04-30 | 2016-07-16 | 英塞特公司 | 製備jak1抑制劑之方法及其新形式 |
WO2016026975A1 (en) | 2014-08-21 | 2016-02-25 | Ratiopharm Gmbh | Salt of (r)-3-(4-(7h-pyrrolo [2,3-d] pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid |
WO2016026974A1 (en) | 2014-08-21 | 2016-02-25 | Ratiopharm Gmbh | Oxalate salt of ruxolitinib |
WO2016035014A1 (en) | 2014-09-01 | 2016-03-10 | Sun Pharmaceutical Industries Limited | Processes for the preparation of ruxolitinib phosphate |
WO2016063294A2 (en) | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof |
CN107278205A (zh) | 2015-02-24 | 2017-10-20 | 辉瑞大药厂 | 用作抗癌药的取代的核苷衍生物 |
CN106397443A (zh) | 2015-07-17 | 2017-02-15 | 浙江九洲药业股份有限公司 | 一种吡咯嘧啶类衍生物中间体的制备方法 |
CZ2015575A3 (cs) | 2015-08-26 | 2017-03-08 | Zentiva, K.S. | Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava |
AU2016379454B2 (en) | 2015-12-23 | 2021-01-28 | The University Of British Columbia | Lipid-linked prodrugs |
EP3398952B1 (en) * | 2015-12-31 | 2021-07-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Synthesis process of ruxolitinib |
CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
CN107513069A (zh) | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
IN201641026603A (es) | 2016-08-04 | 2018-02-09 | ||
CN107722012B (zh) | 2016-08-11 | 2020-05-29 | 斯福瑞(南通)制药有限公司 | 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法 |
CN107759623B (zh) | 2016-08-23 | 2020-08-14 | 苏州旺山旺水生物医药有限公司 | Jak抑制剂的中间体及其制备方法 |
CN107759601B (zh) | 2016-08-23 | 2020-09-11 | 苏州旺山旺水生物医药有限公司 | 一种jak抑制剂及其盐的制备方法 |
JP2019532944A (ja) | 2016-09-23 | 2019-11-14 | セルイプセ | Limk介在性疾患における、limキナーゼ阻害剤、医薬組成物および使用方法 |
CN109651424B (zh) | 2017-10-11 | 2021-01-22 | 新发药业有限公司 | 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法 |
US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
DK3746429T3 (da) | 2018-01-30 | 2022-05-02 | Incyte Corp | Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on) |
PT3797099T (pt) | 2018-05-21 | 2024-02-05 | Pi Industries Ltd | Método para preparar compostos heterocíclicos substituídos |
KR20210124345A (ko) | 2019-02-06 | 2021-10-14 | 콘서트 파마슈티컬즈, 인크. | 거울상 이성질체 풍부한 jak 억제제를 제조하는 방법 |
CN110724145A (zh) | 2019-11-01 | 2020-01-24 | 廖文杰 | 一种医药中间体4-氯吡咯并嘧啶的合成方法 |
CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
US11905292B2 (en) | 2020-08-18 | 2024-02-20 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
CA3226714A1 (en) | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
CN113480546A (zh) | 2021-07-30 | 2021-10-08 | 江苏君若药业有限公司 | 巴瑞克替尼及其衍生物的制备 |
-
2021
- 2021-08-17 CA CA3192055A patent/CA3192055A1/en active Pending
- 2021-08-17 IL IL300557A patent/IL300557A/en unknown
- 2021-08-17 CN CN202180068687.0A patent/CN117043152A/zh active Pending
- 2021-08-17 PE PE2023000303A patent/PE20231308A1/es unknown
- 2021-08-17 AR ARP210102307A patent/AR123268A1/es unknown
- 2021-08-17 JP JP2023512178A patent/JP2023538614A/ja active Pending
- 2021-08-17 CR CR20230130A patent/CR20230130A/es unknown
- 2021-08-17 MX MX2023002035A patent/MX2023002035A/es unknown
- 2021-08-17 TW TW110130370A patent/TW202212341A/zh unknown
- 2021-08-17 US US17/404,461 patent/US11897889B2/en active Active
- 2021-08-17 WO PCT/US2021/046286 patent/WO2022040172A1/en active Application Filing
- 2021-08-17 BR BR112023002939A patent/BR112023002939A2/pt unknown
- 2021-08-17 AU AU2021329301A patent/AU2021329301A1/en active Pending
- 2021-08-17 KR KR1020237009250A patent/KR20230095923A/ko unknown
- 2021-08-17 EP EP21766776.5A patent/EP4200278A1/en active Pending
-
2023
- 2023-02-16 CL CL2023000482A patent/CL2023000482A1/es unknown
- 2023-03-16 EC ECSENADI202319419A patent/ECSP23019419A/es unknown
- 2023-03-16 CO CONC2023/0003286A patent/CO2023003286A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2023003286A2 (es) | 2023-06-09 |
ECSP23019419A (es) | 2023-04-28 |
CA3192055A1 (en) | 2022-02-24 |
WO2022040172A1 (en) | 2022-02-24 |
JP2023538614A (ja) | 2023-09-08 |
CN117043152A (zh) | 2023-11-10 |
TW202212341A (zh) | 2022-04-01 |
AR123268A1 (es) | 2022-11-16 |
BR112023002939A2 (pt) | 2023-04-25 |
KR20230095923A (ko) | 2023-06-29 |
IL300557A (en) | 2023-04-01 |
US20220056034A1 (en) | 2022-02-24 |
AU2021329301A1 (en) | 2023-04-13 |
PE20231308A1 (es) | 2023-08-24 |
US11897889B2 (en) | 2024-02-13 |
MX2023002035A (es) | 2023-06-12 |
EP4200278A1 (en) | 2023-06-28 |
CL2023000482A1 (es) | 2023-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20230130A (es) | Proceso e intermedios para preparar un inhibidor de jak1 | |
CR20220354A (es) | Inhibidores de egfr | |
PH12019502264A1 (en) | Fused imidazo-piperidine jak inhibitors compound | |
MX2019012815A (es) | Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo. | |
MX2021015546A (es) | Proceso para preparar 4-amino-piridazinas. | |
MX2021008965A (es) | Proceso para preparar un agonista dual de gip/glp1. | |
MX2021013326A (es) | Sintesis de omecamtiv mecarbil. | |
MX2019010642A (es) | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. | |
MX2021003070A (es) | Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino. | |
MX2023002037A (es) | Proceso e intermediarios para preparar un inhibidor de las cinasas de janus (jak). | |
SG10201902609TA (en) | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same | |
MX2020012900A (es) | Potentes inhibidores de d-aminoacido oxidasa (daao) y sus usos. | |
PH12020500129A1 (en) | Inhibitors of rory | |
EA202090933A1 (ru) | Способ получения гербицидных соединений пиридазинона | |
MX2019001228A (es) | Metodo de produccion del compuesto de pirazol-amida. | |
SG11201810725WA (en) | Novel β-lactamase inhibitors | |
MX2021004288A (es) | Nuevo proceso para la sintesis de derivados de piperazinil-etoxi-bromofenilo y su aplicacion en la produccion de compuestos que los contienen. | |
MX2023004950A (es) | Proceso para purificacion de pleuromutilinas. | |
MX2023000970A (es) | Metodo de preparacion de aminofuranos. | |
CL2021000663A1 (es) | Proceso para la producción de gas de síntesis. | |
MX2020006070A (es) | Proceso de producción de n-acetil taurinato de magnesio. | |
MX2021009423A (es) | Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). | |
MX2022006178A (es) | Composiciones que comprenden tricianohexano. | |
MX2019000984A (es) | Proceso para preparacion de indanonas. | |
MX2022006044A (es) | Proceso para preparar analogos de araquidonoiletanolamina. |